Lack of hypotriglyceridemic effect of gemfibrozil as a consequence of age-related changes in rat liver PPARα

Biochemical Pharmacology

Volumn 67, Issue 1, 2004, Pages 157-166

  Sanguino, Elena ^a   Ramón, Miguel ^a   Michalik, Liliane ^b   Wahli, Walter ^b   Alegret, Marta ^a   Sánchez, Rosa M ^a   Vázquez Carrera, Manuel ^a   Laguna, Juan C ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Fibrates; Gemfibrozil; Hypolipidemic effect; Old age; PPAR ; Rat liver

Indexed keywords

ACYL COENZYME A DEHYDROGENASE; CARNITINE PALMITOYLTRANSFERASE; GEMFIBROZIL; LEPTIN; MESSENGER RNA; MITOCHONDRIAL MEDIUM CHAIN ACYL COENZYME A DEHYDROGENASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

AGING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; GENE TARGETING; HYPERTRIGLYCERIDEMIA; HYPOTHESIS; LIVER METABOLISM; MALE; NONHUMAN; PEROXISOME; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RAT;

EID: 0344255575     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2003.08.034     Document Type: Article

References (40)

1. Knight J.A. The biochemistry of aging. Adv. Clin. Chem. 35:2001;1-62.
2. Corti M.-C., Barbato G.-M., Baggio G. Lipoprotein alterations and atherosclerosis in the elderly. Curr. Opin. Lipidol. 8:1987;236-241.
3. Watts G.F., Dimmitt S.B. Fibrates, dyslipoproteinemia and cardiovascular diseases. Curr. Opin. Lipidol. 10:1999;561-574.
4. Neve B.P., Fruchart J.-C., Staels B. Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis. Biochem. Pharmacol. 60:2000;1245-1250.
5. Escher P., Wahli W. Peroxisome proliferator-activated receptors: insight into multiple cellular functions. Mutat. Res. 448:2000;121-138.
6. Parini P., Angelin B., Rudling M. Cholesterol and lipoprotein metabolism in aging: reversal of hypercholesterolemia by growth hormone treatment in old rats. Arterioscler Thromb. Vasc. Biol. 19:1999;832-839.
7. Toth M.J., Tchernof A. Lipid metabolism in the elderly. Eur. J. Clin. Nutr. 54:2000;S121-S125.
8. Alegret M., Ferrando R., Vázquez M., Adzet T., Merlos M., Laguna J.C. Relationship between plasma lipids and palmitoyl-CoA hydrolase and synthetase activities with peroxisomal proliferation in rats treated with fibrates. Br. J. Pharmacol. 112:1994;551-556.
9. Verd J.C., Peris C., Alegret M., Díaz C., Hernández G., Vázquez M., Adzet T., Laguna J.C., Sánchez R.M. Different effect of simvastatin and atorvastatin on key enzymes involved in VLDL synthesis and catabolism in high fat/cholesterol fed rabbits. Br. J. Pharmacol. 127:1999;1479-1485.
10. Freeman W.M., Walker S.J., Vrana E.V. Quantitative RT-PCR: pitfalls and potential. BioTechniques. 26:1999;112-125.
11. Dignam J.D., Lebovitz R.M., Roeder R.G. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acid Res. 11:1983;1475-1489.
12. Sonnenberg J.L., Macgregor-Leon P.F., Curran T., Morgan J.I. Dynamic alterations occur in the levels and composition of transcription factor AP-1 complexes after seizure. Neuron. 3:1989;359-365.
13. Bradford M.M. A rapid sensitive method for the quantitation of microgram quantities of protein utilizing the principles of protein-dye binding. Anal. Biochem. 72:1976;248-254.
14. Kim J.B., Spotts G.D., Halvorsen Y., Shih H., Ellenberger T., Towle H.C., Spiegelman B.M. Dual DNA binding specificity of ADD1/SREBP1 controlled by a single amino acid in the basic helix-loop-helix domain. Mol. Cell. Biol. 15:1995;2582-2588.
15. Lemberger T., Saladin R., Vázquez M., Assimacopoulos F., Staels B., Desvergne B., Wahli W., Auwerx J. Expression of the peroxisome proliferator-activated receptor α gene is stimulated by stress and follows a diurnal rhythm. J. Biol. Chem. 271:1996;1764-1769.
16. Rodríguez R., Noé V., Cabrero A., Ciudad C.J., Laguna J.C. Differences in the formation of PPARα-RXR/acoPPRE complexes between responsive and non responsive species upon fibrate administration. Mol. Pharmacol. 58:2000;185-193.
17. Louet J.-F., Le May C., Pégorier J.-P., Decaux J.-F., Girard J. Regulation of liver carnitine palmitoyltransferase I gene expression by hormones and fatty acids. Biochem. Soc. Trans. 29:2001;310-316.
18. Gulick T., Cresci S., Caira T., Moore D.D., Kelly D.P. The peroxisomal proliferator-activated receptor regulates mitochondrial fatty acid oxidative gene expression. Proc. Natl. Acad. Sci. U.S.A. 91:1994;11012-11016.
19. Spencer N.F.L., Poynter M.E., Suhn-Young I., Daynes R.A. Constitutive activation of NF-κB in an animal model of aging. Int. Immunol. 9:1997;1581-1588.
20. Poynter M.E., Daynes R.A. Peroxisome proliferator-activated receptor α activation modulates cellular redox status represses nuclear factor-κB signaling, and reduces inflammatory cytokine production in aging. J. Biol. Chem. 273:1998;32833-32841.
21. Horton J.D., Shimomura I. Sterol regulatory element-binding proteins: activators of cholesterol and fatty acid biosynthesis. Curr. Opin. Lipidol. 10:1999;143-150.
22. Wang Z.-W., Pan W.-T., Lee Y., Kakuma T., Zhou Y.-T., Unger R.H. The role of leptin in the lipid anormalities of aging. FASEB J. 15:2001;108-114.
23. Lee Y., Hirose H., Zhou Y.-T., Esser V., McGarry J.D., Unger R.H. Increased lipogenic capacity of the islets of obese rats: a role in the pathogenesis of NIDDM. Diabetes. 46:1997;408-413.
24. Lee Y., Wang M.-Y., Kakuma T., Wang Z.-W., Babcook E., McCorkle K., Higa M., Zhou Y.-T., Unger R.H. Liporegulation in diet-induced obesity. The antisteatotic role of hyperleptinemia. J. Biol. Chem. 276:2001;5629-5635.
25. Zhou Y.-T., Wang Z.-W., Higa M., Newgard C.B., Unger R.H. Reversing adipocyte differentiation: implications for treatment of obesity. Proc. Natl. Acad. Sci. U.S.A. 96:1999;2391-2395.
26. James R.W. Diabetes and other coronary heart disease risk equivalents. Curr. Opin. Lipidol. 12:2001;425-431.
27. Grabiely I., Ma X.H., Yang X.M., Rossetti L., Barzilai N. Leptin resistance during aging is independent of fat mass. Diabetes. 51:2002;1016-1021.
28. Lemberger T., Staels B., Saladin R., Desvergne B., Auwerx J., Wahli W. Regulation of the peroxisome proliferator-activated receptor α gene by glucocorticoids. J. Biol. Chem. 269:1994;24527-24530.
29. Carlsson L., Lindén D., Jalouli M., Oscarsson J. Effects of fatty acids and growth hormone on liver fatty acid binding protein and PPARα in rat liver. Am. J. Physiol. Endocrinol. Metab. 281:2001;E772-E781.
30. Steinger H.H., Sorensen H.N., Tugwood J.D., Skrede S., Spydevold O., Gautvik K.M. Dexamethasone and insulin demonstrate marked and opposite regulation of the steady-state mRNA level of the peroxisomal proliferator-activated receptor (PPAR) in hepatic cells - hormonal modulation of fatty-acid-induced transcription. Eur. J. Biochem. 225:1994;967-974.
31. Lee Y., Yu X., Gonzales F., Mangelsdorf D.J., Wang M.Y., Richardson Witters L.A., Unger R.H. PPAR alpha is necessary for the lipopenic action of hyperleptinemia on white adipose and liver tissue. Proc. Natl. Acad. Sci. U.S.A. 99:2002;11848-11853.
32. Akiyama T.E., Nicol C.J., Fieve C., Staels B., Ward J.M., Auwerx J., Lee S.S.T., Gonzalez F.J., Peters J.M. Peroxisome proliferator-activated receptor-α regulates lipid homeostasis. J. Biol. Chem. 276:2001;39088-39093.
33. Galli A., Pinaire J., Fischer M., Dorris R., Crabb D.W. The transcriptional and DNA binding activity of peroxisome proliferator-activated receptor α is inhibited by ethanol metabolism. A novel mechanism for the development of ethanol-induced fatty liver. J. Biol. Chem. 276:2001;68-75.
34. Lee S.S., Pineau T., Drago J., Lee E.J., Owens J.W., Kroetz D.L., Fernandez-Salguero P.M., Westphal H., Gonzalez F.J. Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol. Cell. Biol. 15:1995;3012-3022.
35. Peters J.M., Hennuyer N., Staels B., Fruchart J.C., Fievet C., Gonzalez F.J., Auwerx J. Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor α-deficient mice. J. Biol. Chem. 272:1997;28307-28312.
36. Tordjman K., Bernal-Mizrachi C., Zemany L., Weng S., Feng C., Zhang F., Leone T.C., Coleman T., Kelly D.P., Semenkovich C.F. PPARalpha deficiency reduces insulin resistance and atherosclerosis in apoE-null mice. J. Clin. Invest. 107:2001;1025-1034.
37. Mooradian A.D., Hurd R., Chehade J., Pun K., Haas M.J. Age-related changes in plasma leptin binding activity in rats: a comparison of a simple acid-ethanol precipitation technique with column chromatography. Proc. Soc. Exp. Biol. Med. 224:2000;273-277.
38. Yamauchi T., Kamon J., Waki H., Murakami K., Motojima K., Komeda K., Ide T., Kubota N., Terauchi Y., Tobe K., Miki H., Tsuchida A., Akanuma Y., Nagai R., Kimura S., Kadowaki T. The mechanisms by which both heterozygous peroxisome proliferator-activated receptor γ (PPARγ) deficiency and PPARγ agonist improve insulin resistante. J. Biol. Chem. 276:2001;41245-41254.
39. Clarke S.D. Polyunsaturated fatty acid regulation gene transcription: a molecular mechanism to improve the metabolic syndrome. J. Nutr. 131:2001;1129-1132.
40. Xu J., Nakamura M.T., Cho H.P., Clarke S.D. Sterol regulatory element binding protein-1 expression is suppressed by dietary polyunsaturated fatty acids. A mechanism for the coordinate suppression of lipogenic genes by polyunsaturated fats. J. Biol. Chem. 274:1999;23577-23583.